Brainstorm Cell Therapeutics inks deal with Catalent to boost NurOwn
Brainstorm Cell Therapeutics Inc. (BCLI) announced that it has entered into a deal with Catalent (CTLT) for manufacturing of NurOwn. The therapy is currently being tested for treating amyotrophic lateral sclerosis. It works by inducing mesenchymal stem cells to express higher number of neurotrophic factors.
Under the terms of the agreement, Catalent will be responsible for transferring the manufacturing process to its new manufacturing site in Texas. It will also undertake the obligation of fulfilling future CGMP clinical supply of the therapy from the new site. Chaim Lebovits, Chief Executive Officer of BrainStorm Cell Therapeutics, said: We know that ALS patients are in urgent need of a new treatment option. If NurOwn is successful in the current clinical trials, this agreement will be integral to ensuring rapid access for patients.
NurOwn cells have emerged as a prominent promising therapy for neurodegenerative disorders. MSC-NTF cells are produced from mesenchymal stem cells. These autologous, bone marrow-derived cells are expanded and differentiated ex vivo. MSCs are converted into MSC-NTF cells by inducing them to secrete high levels of neurotrophic factors under patented conditions. Autologous MSC-NTF cells are able to distribute multiple NTFs and immunomodulatory cytokines directly to the site of damage. This helps in provoking desirable biological effect and slow or stabilize disease progression.
The company is currently working on a double-blind, placebo-controlled, repeat-dosing NurOwn Phase 3 study. The trial has enrolled 200 patients for this purpose. The company has also been granted the FDA approval to start a Phase 2 trial for testing the drug candidate for treating progressive MS. This open label, multicenter trial started the enrolment in March 2019.
Catalent is a leading company in the field of developing solutions for drugs, biologics, cell and gene therapies. It is a full-service partner for adeno-associated virus (AAV) and lentiviral vectors, and CAR-T immunotherapies.
Brainstorm mainly deals in developing autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. Autologous MSC-NTF cells have been granted Orphan Drug status designation by the US FDA and the European Medicines Agency for treating ALS. The company plans to use the positive data from the pivotal study for supporting its application to the FDA.
Brainstorm is currently working in a wide array of indications including ALS, Progressive Multiple Sclerosis, Huntingtons Disease, Parkinsons Disease and Autism Spectrum Disorder. For ALS, the company is currently carrying out Phase 3 studies, while for progressive MS, the program is in Phase 2 stages. For the remaining indications, Brainstorm is carrying out pre-clinical programs.
Analysis: Brainstorm candidate targets a global ALS + progressive MS treatment market valued at ~$791 million in 2018 estimated to reach ~$1,235 million in 2026 at a CAGR of 5.7%. The company has a market capitalization of ~$339 million on a stock price of $10.75, at midpoint of its 52-week range: $3.58-$17.95. One Wall Street analyst is bullish with a price target of $26.50. Major shareholders are the public with over 59% shares and institutions with over 27% shares, while private corporations and insiders hold about 7% each of the 31.57 million shares outstanding. The company has a cash balance of ~$29 million against a debt of $1.5 million, providing a runway of just about 12 months, considering cash burn of $23 million in fiscal 2019 and $27.9 million in the TTM.
Investment Thesis: While the stock has shown steep increase in the past one year, the new deal is expected to provide further push to the price. The company has important catalysts such as the likely approval of the drug candidate coming up.
Aurinia Pharmaceuticals Inc. (AUPH) announced integrated efficacy and pharmacokinetic for voclosporin for treating lupus nephritis. The data has been collated from the companys AURA-LV and AURORA pivotal trials involving 534 patients.
The data showed that 268 patients with lupus nephritis showed statistically significant superior and faster Renal Response rates compared to other cohort of 266 patients. The former group of patients was treated with voclosporin in combination with mycophenolate mofetil (MMF) and low-dose steroids while the latter group was given MMF and steroids alone.
The data also demonstrated that the treatment brought 43.7 percent higher Renal Response rate whereas the control arm showed 23.3 percent at one year. At six months, the respective rates were 31.7 percent and 20.3 percent. Neil Solomons, M.D., Chief Medical Officer of Aurinia, said, Together with the supportive pharmacokinetic data, these findings add to the growing body of information available on voclosporin as an investigational drug that could provide an important treatment approach for people dealing with LN.
Both the AURA-LV and AURORA studies share the similar designed and were carried out in comparable patient populations. Subjects in both the studies were administered the recommended voclosporin dose of 23.7 mg twice daily or with matching placebo. The patient populations were pooled for an integrated analysis.
The data formed a part of the companys New Drug Application to the FDA. The regulatory agency has accepted the NDA and granted it the Priority Review status. The PDUFA target action date for the application has been set at January 22, 2021.
Analysis: Aurinia's candidate is targeting lupus nephritis, part of the systemic lupus erythematosus (SLE) market that was worth $1.87 billion in 2017 and estimated to reach $3.08 billion by 2025 at a CAGR of 7%. The company has a market capitalization of ~$1.97 billion on a price of $15.66, in a 52-week range between $4.57 and $21.93. 8 Wall Street analysts are very bullish and 2 are bullish with an average score of 4.8/5, and a price target of $25.10. Major shareholders are institutions and the public each with about 44% holding, with hedge funds, corporations and insiders holding 7.53%, 2.06% and 3.09%, respectively. The company has a debt of $6.2 million and cash balance of $264.35 million. Cash burn & cost of revenue were $23.7 and $52.9 million, respectively, in fiscal 2019, and $41.6 million and $56 million, respectively, in the TTM. The company estimates a revenue of ~$93 million in 2021.
Investment Thesis: With a strong development pipeline, the stock has strong future ahead. Currently, it is trading at considerable discount to its previous highs and may be good for initiating a position.
Aldeyra Therapeutics Inc. (ALDX) announced new data from the Phase 2 allergen chamber clinical trial of reproxalap ophthalmic solution in allergic conjunctivitis. The data did not show any safety or tolerability concerns. The company has advanced the 0.25% concentration of reproxalap to the Phase 3 INVIGORATE Trial.
The Phase 2 clinical trial was a randomized, double-masked, crossover, vehicle-controlled study. It involved 70 patients with allergic conjunctivitis who were evaluated over 3.5 hours in an allergen chamber of aerosolized ragweed pollen. Todd C. Brady of Aldeyra said, The new data presented at AAO this year further support the clinical utility of reproxalap, the first novel mechanistic approach in late-stage allergic conjunctivitis clinical trials in decades, as uniquely effective.
Both the dosage levels of reproxalap at 0.25 percent and 0.5 percent statistically significant and clinically relevant improvements in subject-reported ocular itching and tearing and investigator-assessed ocular redness. The data showed the prophylactic and treatment effect of drug. The time to event responder analyses showed the clinical relevance of the superiority of reproxalap over vehicle for ocular itching and ocular redness.
The Phase 3 INVIGORATE Trial is a randomized, double-masked, crossover, vehicle-controlled clinical and will evaluate the efficacy and safety of reproxalap 0.25% compared to vehicle using an allergen chamber. The primary endpoint of the trial will be subject-reported ocular itching score. Aldeyra is currently carrying out recruitment for the Phase 3 and the expects the topline data to be out in the first half of 2021.
Analysis: Aldeyra's ophthalmic solution will target an allergic conjunctivitis global market that was $2.5 billion in 2019 and estimated to reach $3.05 billion by 2027. Aldeyra has a market capitalization of $295.16 million on a share price of $7.64, which is near the 52-week high of $8.7. The company's 38.63 million shares are majorly held by the public with about 62% holding, whereas institutions hold about 36.5% and insiders about 1.5%. 5 Wall Street analysts are very bullish and 1 analyst is bullish giving an average score of 4.83/5 and a price target of $26.83. The company has a debt of $14.93 million and a cash balance of $56.19 million. Cash burn in fiscal 2019 was $56.5 million, while in the TTM it is $48.6 million.
Investment Thesis: The company is expected to provide updates about its different programs including COVID-19 treatment. These catalysts are expected to offer positive impetus to the stock.
Thanks for reading. At the Total Pharma Tracker, we offer the following:-
Our Android app and website features a set of tools for DIY investors, including a work-in-progress software where you can enter any ticker and get extensive curated research material.
For investors requiring hands-on support, our in-house experts go through our tools and find the best investible stocks, complete with buy/sell strategies and alerts.
Sign up now for our free trial, request access to our tools, and find out, at no cost to you, what we can do for you.
Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
See the rest here:
Brainstorm Deal To Boost NurOwn, And Other News: The Good, Bad And Ugly Of Biopharma - Seeking Alpha
- Mesenchymal stem cell based therapies for uveitis: a systematic review of preclinical studies | Eye - Nature.com - April 10th, 2024
- Development of exosome therapy to treat inflammatory bowel disease by VesiCURE Therapeutics - StreetInsider.com - April 10th, 2024
- Adipose Derived Stem Cell Therapy Market Will Show the Highest Growth Rates, Incredible Demand by 2031 - WhaTech - April 3rd, 2024
- Injectable microspheres adhering to the cartilage matrix promote rapid reconstruction of partial-thickness cartilage defects - ScienceDirect.com - March 30th, 2024
- Safety and Potential Effect of Intrauterine Infusion of Autologous Adipose Tissue-Derived Regenerative Cells in ... - Cureus - March 30th, 2024
- Instructing iPS cell-derived mesenchymal stem cells to inhibit abnormal bone formation in FOP - Medical Xpress - March 28th, 2024
- Clinical application of mesenchymal stem cell in regenerative medicine ... - March 22nd, 2024
- Mesenchymal Stem Cells: The Past Present and Future - March 22nd, 2024
- CytoMed Diversifies into Regenerative Medicine after Research Collaboration with Singapore's Sengkang General ... - Yahoo Finance - March 20th, 2024
- Overexpression of Wnt5a promoted the protective effect of mesenchymal stem cells on Lipopolysaccharide-induced ... - BMC Infectious Diseases - March 20th, 2024
- Mesenchymal Stem Cells: What We Have Learned and How to Manage Them - MDPI - March 17th, 2024
- Mesenchymal stem cells and their microenvironment - March 17th, 2024
- Mesenchymal stem/stromal cells as a valuable source for the treatment ... - March 17th, 2024
- Proteomic characterization of hUC-MSC extracellular vesicles and evaluation of its therapeutic potential to treat ... - Nature.com - March 13th, 2024
- The impact understanding of exosome therapy in COVID-19 and preparations for the future approaches in dealing with ... - Nature.com - March 13th, 2024
- CytoMed Therapeutics Limited Announces Research Collaboration with Singapore Sengkang General Hospital to ... - Yahoo Finance UK - March 7th, 2024
- CytoMed Therapeutics Limited Announces Research Collaboration with Singapore Sengkang General Hospital to ... - Yahoo Finance - March 6th, 2024
- Combatting osteoarthritis with cartilage replacement therapy - Drug Target Review - March 3rd, 2024
- Ethical considerations in Stem Cell therapy for ALS - Cyprus Mail - February 27th, 2024
- Therapeutic Solutions International Files Patent on Facilitating Effects of JadiCells on Gene Therapy Mediated Cell ... - Business Wire - February 27th, 2024
- Stem Cell Therapy for Ulcerative Colitis - Health Central - February 27th, 2024
- Expanding the Horizons of Cell and Gene Therapy - RegMedNet - February 24th, 2024
- Early differentiation of mesenchymal stem cells is reflected in their dielectrophoretic behavior | Scientific Reports - Nature.com - February 22nd, 2024
- Orthopaedics Department's Regenerative Research Highlighted at ORS Annual Meeting - InventUM - University of Miami - February 20th, 2024
- Cellular uptake and in vivo distribution of mesenchymal-stem-cell-derived extracellular vesicles are protein corona ... - Nature.com - February 18th, 2024
- New University spin-out developing novel adult stem cell-based Therapies - News - University of Liverpool - News - February 15th, 2024
- Examining the potential of the common bovine as a potential therapeutic research model - Medical Xpress - February 15th, 2024
- Intentional Interference: Genetic Engineering Medium Aids The Transfection Of MSCs With siRNA - BioProcess Online - February 15th, 2024
- Cellular senescence is associated with osteonecrosis of the femoral head while mesenchymal stem cell conditioned ... - Nature.com - February 9th, 2024
- Stem Cell Therapy for Crohns Disease Shows Promising Results - RegMedNet - February 9th, 2024
- Targeted transcriptomic analysis of synovial tissues from horses with septic arthritis treated with immune-activated ... - American Veterinary Medical... - February 7th, 2024
- Mesenchymal Stem Cell Immunomodulation: Mechanisms and ... - Cell Press - February 7th, 2024
- New Cell Therapy for ARDS: A Groundbreaking Development and Other Respiratory Health Breakthroughs - Medriva - February 7th, 2024
- Effective treatment of optic neuropathies by intraocular delivery of MSC-sEVs through augmenting the G-CSF ... - pnas.org - January 31st, 2024
- Global Stem Cell Therapy Industry Outlook to 2028, Driven by Therapeutic Innovations and Clinical Advancements ... - Yahoo Finance - January 29th, 2024
- Out-of-this-world study will test how stem cells function in space - YP - January 29th, 2024
- The Applications of Cell Therapy - Technology Networks - January 26th, 2024
- STEM CELL THERAPY FOR MS COST: WHAT YOU NEED TO KNOW? - Island Echo - January 24th, 2024
- Understanding Neuromyelitis Optica: Role of NF-B and Therapeutic Potential - Medriva - January 20th, 2024
- Faculty member Arnold Caplan passes away The Daily The Daily - The Daily | Case Western Reserve University - January 18th, 2024
- Effects of fine particulate matter on bone marrow-conserved hematopoietic and mesenchymal stem cells: a systematic ... - Nature.com - January 11th, 2024
- Expression of HLA-DR by mesenchymal stromal cells in the platelet lysate era: an obsolete release criterion for MSCs ... - Journal of Translational... - January 11th, 2024
- NurOwn and its exosomes for ALS given patents in Europe, elsewhere - ALS News Today - January 8th, 2024
- Single-cell analysis reveals the stromal dynamics and tumor-specific characteristics in the microenvironment of ovarian ... - Nature.com - January 8th, 2024
- First in Class Combination Stem Cell and Exosome Therapy to Treat Pulmonary Fibrosis in Long Haul Covid Patients ... - Yahoo Finance - January 4th, 2024
- Choosing the Right Excipients for MSC and iPSC Therapies - Pharmaceutical Technology Magazine - January 4th, 2024
- Mitochondria Transplantation Therapy It's Farther Along Than You Think - BioProcess Online - January 2nd, 2024
- Embryonic-stem-cell-derived mesenchymal stem cells relieve experimental contact urticaria by regulating the functions ... - Nature.com - December 21st, 2023
- Type I collagen and fibromodulin enhance the tenogenic phenotype of hASCs and their potential for tendon ... - Nature.com - December 19th, 2023
- Could the 'central dogma' of biology be misleading bioengineers? - Phys.org - December 13th, 2023
- The Risks of Stem Cell and Exosome Treatments for Long COVID: A Call for Stricter Regulations - Medriva - December 13th, 2023
- Mesenchymal stem cells from biology to therapy - PMC - December 11th, 2023
- The Safety and Efficacy of Human Umbilical Cord-Derived ... - Cureus - December 5th, 2023
- The pivotal role of Nrf2 signal axis in IDD | JIR - Dove Medical Press - December 5th, 2023
- Futuristic Novel Therapeutic Approaches in the Treatment of ... - Cureus - December 3rd, 2023
- Cartilage's Contribution in Otology: A Comprehensive Review of Its ... - Cureus - December 3rd, 2023
- Mesenchymal stem or stromal cells: a review of clinical applications ... - November 29th, 2023
- Comparative evaluation of 3D-printed and conventional implants in ... - Nature.com - November 29th, 2023
- Expression of E-cadherin and N-cadherin in Epithelial-to ... - Cureus - November 29th, 2023
- Enhancing the immunosuppressive properties of human umbilical cord mesenchymal stem cells - Phys.org - November 29th, 2023
- 'Great Potential' in Stem Cell Therapies for Knee Osteoarthritis ... - Pain News Network - November 25th, 2023
- Dietary Sources, Bioavailability, and Functions of Ascorbic Acid ... - Cureus - November 25th, 2023
- FY 2024 VA-Funded Projects - VA's Office of Research and Development - November 25th, 2023
- Real-world data suggest effectiveness of the allogeneic ... - Journal of Translational Medicine - November 23rd, 2023
- Mesenchymal Stem Cells: Characteristics, Function, and Application - November 23rd, 2023
- Combined application of therapeutic viruses and nanomaterials to ... - News-Medical.Net - November 23rd, 2023
- Progress in the Development of Stem Cell-Derived Cell-Free ... - Dove Medical Press - November 23rd, 2023
- Improving the therapeutic efficacy of oncolytic viruses for cancer ... - Journal of Translational Medicine - November 23rd, 2023
- 11.22.23 -- How To Lose A Batch In 10 Days - BioProcess Online - November 23rd, 2023
- The Pros and Cons of Mesenchymal Stem Cell-Based Therapies - November 19th, 2023
- Leptin's influence on MMP-1 expression | JIR - Dove Medical Press - November 15th, 2023
- TWIST1 and TSG6 are coordinately regulated and function as ... - Science - November 11th, 2023
- Association between severe acute malnutrition in childhood and ... - BioMed Central - November 11th, 2023
- Global Market for Treatments for Syndromes of Progressive Ataxia and Weakness Disorders - Yahoo Finance - November 11th, 2023
- Stem Cell Restore Reviews - Does It Work? Real Green Valley ... - The Daily World - November 11th, 2023
- Biological and genetic characterization of a newly established ... - Nature.com - November 11th, 2023
- Placental Stem Cell Collection and Storage Industry Scope ... - Argyle Report - November 9th, 2023
- In Vitro Evaluation of Light-Induced Cytotoxic Property: Synergistic ... - Cureus - November 9th, 2023
- UF professor launches nonprofit to equalize cell-based therapy access - Mainstreet Daily News Gainesville - November 7th, 2023
- Who are the leading innovators in cell immunomodulation for the ... - Pharmaceutical Technology - November 7th, 2023
Recent Comments